CLDX
Celldex Therapeutics (CLDX) dropped 10% after-hours following disappointing results from a mid-stage...
Article Summary
SELL- Celldex Therapeutics (CLDX) dropped 10% after-hours following disappointing results from a mid-stage prurigo-nodularis trial, with the drug barzolvolimab failing to show meaningful reduction in worst daily itch at week 12 compared with placebo.
- The trial failed to meet its main goal, with secondary measures including doctor assessments of skin lesions and itch relief also showing no clear advantage for the drug.
- Celldex said it is discontinuing further development of the drug, though it will continue advancing the drug in late-stage trials for chronic spontaneous urticaria with data expected this fall.
- The drug produced strong sustained depletion of mast cells, but this biological effect did not translate into symptom improvement, with treatment continuing through week 24 remaining similar to placebo.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | -88.5% | 25% | 0.0 ptsDeclining (-88.5%) - NOT a growth stock |
| EPS Growth Next 5Y ? | 5.0% | 25% | 20.0 ptsWeak (5.0%) - Low expectations |
| Target Price Upside ? | 60.6% | 20% | 100.0 ptsMassive Upside (60.6%) - Target: $57.27 vs Current: $35.66 |
| Gross Margin % ? | -288.8% | 15% | 10.0 ptsRazor-Thin (-288.8%) - Weak pricing power |
| Drawdown from 52-Wk High ? | -11.5% | 15% | 40.0 ptsMild Pullback (-11.5%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About CLDX
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.
- The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
- It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation.
- Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.